IQVIA Logo
Contact Us
178_Female scientist in lab

Psoriasis Drug Discovery Services

Advance psoriasis therapeutics with a clinically relevant preclinical model designed to support candidate selection and mechanism validation.

Contact us

Imiquimod-Induced Psoriasis Mouse Model for Translational Drug Discovery

Selecting the right preclinical model is critical to understanding efficacy, target engagement and translational potential. The imiquimod-induced psoriasis mouse model enables the evaluation of novel therapies targeting inflammatory and immune-mediated pathways, including IL-23, IL-17, Th17, and emerging immunomodulatory mechanisms. Through integrated pharmacology, biomarker analysis and histopathology services, we generate data that helps you make confident development decisions and reduce program risk.


Comprehensive Psoriasis CRO Services

Our integrated discovery and preclinical development capabilities provide a single partner for generating actionable data throughout the development lifecycle.
In Vivo Psoriasis Pharmacology Studies
Histopathology and Tissue Analysis
Biomarker and Cytokine Profiling
PK/PD Integration

Evaluate therapeutic efficacy across clinically relevant disease endpoints, including:

  • Erythema scoring

  • Skin thickness

  • Scaling assessment

  • Disease severity scoring

  • Longitudinal disease progression analysis

Generate deeper biological insights through:

  • Epidermal hyperplasia assessment

  • Keratinocyte proliferation

  • Immune cell infiltration analysis

  • Tissue pathology scoring

  • Digital pathology

  • Immunohistochemistry

Characterize pharmacological responses with:

  • IL-17 pathway biomarkers

  • IL-23 pathway biomarkers

  • Cytokine and chemokine profiling

  • Immune cell phenotyping

  • Translational biomarker discovery

Improve decision-making with:

  • Exposure-response analysis

  • PK/PD modeling

  • Dose optimization

  • Target engagement assessment
Website Featured Image_PNG-3272_scientist in labcoat wearing nitrile gloves, doing experiments in lab

Translational Psoriasis Models Designed for Drug Development

The imiquimod-induced psoriasis model reproduces key characteristics of human plaque psoriasis, supporting the evaluation of biologics, small molecules, peptides, cell therapies and novel immunomodulatory approaches. This psoriasis model can be used in efficacy studies, for candidate selection, mechanism of action studies, biomarker identification and exploration, and evaluation of combination therapies. Our scientific team partners with you to design customized studies aligned with specific mechanisms of action, development milestones and regulatory requirements.

Why Leading Biopharma Companies Choose Our Psoriasis Research Services

Successful drug development requires more than executing studies. It requires scientific partnership. Our team combines expertise in immunology, inflammation biology, translational pharmacology and biomarker sciences to help generate meaningful, clinically-informed data at every stage of development.

Advantages

  • Dedicated inflammation and immunology specialists

  • Custom study design and consultation

  • Robust translational endpoints

  • Integrated biomarker strategies

  • Rapid study initiation

  • Flexible program support

  • Global-quality scientific standards

  • End-to-end drug discovery services
card-3263_Hand in blue glove holding glass histology slides

Frequently Asked Questions About Psoriasis Drug Discovery Services
What is the imiquimod-induced psoriasis mouse model?

The imiquimod-induced psoriasis mouse model is a widely used preclinical model that reproduces many immunological and pathological features associated with human plaque psoriasis. It is commonly used to evaluate therapeutic efficacy and investigate disease mechanisms relevant to inflammatory skin disorders.
Why is the imiquimod model valuable for psoriasis drug discovery?

The model enables researchers to assess therapeutic effects on clinically relevant disease features, including skin inflammation, epidermal thickening and immune pathway activation. It is particularly valuable for evaluating therapies targeting the IL-23/IL-17 axis and other immune-mediated mechanisms.
What types of therapeutics can be tested?

The model supports evaluation of:

  • Monoclonal antibodies

  • Small molecules

  • Protein therapeutics

  • Peptide therapies

  • Cell therapies

  • Gene therapies

  • Combination therapies
What biomarkers can be analyzed?

Our studies can include cytokine profiling, immune cell characterization, pathway analysis, gene expression studies and pharmacodynamic biomarkers relevant to psoriasis and inflammatory disease biology.
Can studies be customized for specific targets or mechanisms?

Yes. We routinely design customized protocols based on sponsor objectives, therapeutic modality, target biology and development stage. Study endpoints, dosing paradigms and biomarker panels can all be tailored to answer specific scientific questions.
How do psoriasis pharmacology studies support clinical translation?

By integrating efficacy, histopathology, biomarker and PK/PD data, psoriasis pharmacology studies help establish biological proof of concept, support candidate prioritization and generate translational evidence for subsequent clinical development.